Peritoneal inflammation precedes encapsulating peritoneal sclerosis: Results from the GLOBAL Fluid Study

Nephrology Dialysis Transplantation

Volumn 31, Issue 3, 2016, Pages 480-486

  Lambie, Mark R ^a   Chess, James ^b,c   Summers, Angela M ^d   Williams, Paul Ford ^e   Topley, Nicholas ^c   Davies, Simon J ^a  

^a UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^b MORRISTON HOSPITAL   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^e IPSWICH HOSPITAL NHS TRUST   (United Kingdom)

Author keywords

chronic inflammation; encapsulating peritoneal sclerosis; peritoneal dialysis; peritoneal membrane

Indexed keywords

ALPHA INTERFERON; CREATININE; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; DIALYSIS FLUID;

ADULT; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIALYSATE; FEMALE; HUMAN; KIDNEY FUNCTION; MALE; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PERITONITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT DURATION; ADVERSE EFFECTS; BODY FLUID; CLINICAL TRIAL; COMPLICATION; FOLLOW UP; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PERITONEUM; PREVALENCE; RETROSPECTIVE STUDY; UNITED KINGDOM;

BODY FLUIDS; CYTOKINES; DIALYSIS SOLUTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PERITONEUM; PERITONITIS; PREVALENCE; RETROSPECTIVE STUDIES; UNITED KINGDOM;

EID: 84960097489     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv440     Document Type: Article

References (28)

1. Reimold FR, Braun N, Zsengellér ZK, et al. Transcriptional patterns in peritoneal tissue of encapsulating peritoneal sclerosis, a complication of chronic peritoneal dialysis. PLoS One 2013; 8: e56389
2. Lambie M, Chess J, Donovan KL, et al. Independent effects of systemic and peritoneal inflammation on peritoneal dialysis survival. J Am Soc Nephrol 2013; 24: 2071-2080
3. Bos HJ, Meyer F, de Veld JC, et al. Peritoneal dialysis fluid induces change of mononuclear phagocyte proportions. Kidney Int 1989; 36: 20-26
4. Betjes MG, Tuk CW, Struijk DG, et al. Immuno-effector characteristics of peritoneal cells during CAPD treatment: a longitudinal study. Kidney Int 1993; 43: 641-648
5. Sawai A, Ito Y, Mizuno M, et al. Peritoneal macrophage infiltration is correlated with baseline peritoneal solute transport rate in peritoneal dialysis patients. Nephrol Dial Transplant 2011; 26: 2322-2332
6. Lambie ML, John B, Mushahar L, et al. The peritoneal osmotic conductance is low well before the diagnosis of encapsulating peritoneal sclerosis is made. Kidney Int 2010; 78: 611-618
7. Sampimon DE, Coester AM, Struijk DG, et al. The time course of peritoneal transport parameters in peritoneal dialysis patients who develop encapsulating peritoneal sclerosis. Nephrol Dial Transplant 2011; 26: 291-298
8. Morelle J, Sow A, HautemNet al. Interstitial fibrosis restricts osmotic water transport in encapsulating peritoneal sclerosis. J Am Soc Nephrol 2015; 26: 2521-2533
9. Fielding CA, Jones GW, McLoughlin RM, et al. Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity 2014; 40: 40-50
10. Pecoits-Filho R, Carvalho MJ, Stenvinkel P, et al. Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis. Perit Dial Int 2006; 26: 53-63
11. Oh K-H, Jung JY, Yoon MO, et al. Intra-peritoneal interleukin-6 system is a potent determinant of the baseline peritoneal solute transport in incident peritoneal dialysis patients. Nephrol Dial Transplant 2010; 25: 1639-1646
12. Cho J-H, Hur I-K, Kim C-D, et al. Impact of systemic and local peritoneal inflammation on peritoneal solute transport rate in new peritoneal dialysis patients: a 1-year prospective study. Nephrol Dial Transplant 2010; 25: 1964-1973
13. Yamamoto R, Nakayama M, Hasegawa Tet al. High-transport membrane is a risk factor for encapsulating peritoneal sclerosis developing after longterm continuous ambulatory peritoneal dialysis treatment. Adv Perit Dial 2002; 18: 131-134
14. Korte MR, Sampimon DE, Lingsma HF, et al. Risk factors associated with encapsulating peritoneal sclerosis in Dutch EPS study. Perit Dial Int 2011; 31: 269-278
15. Kawaguchi Y, Saito A, Kawanishi H, et al. Recommendations on the management of encapsulating peritoneal sclerosis in Japan, 2005: diagnosis, predictive markers, treatment, and preventive measures. Perit Dial Int 2005; 25 (Suppl 4): S83-S95
16. Sampimon DE, Korte MR, Barreto DL, et al. Early diagnostic markers for encapsulating peritoneal sclerosis: a case-control study. Perit Dial Int 2010; 30: 163-169
17. Goodlad C, Tam FWK, Ahmad S, et al. Dialysate cytokine levels do not predict encapsulating peritoneal sclerosis. Perit Dial Int 2014; 34: 594-604
18. Habib SM, Korte MR, Betjes MGH. Lower mortality and inflammation from post-transplantation encapsulating peritoneal sclerosis compared to the classical form. Am J Nephrol 2013; 37: 223-230
19. Kawaguchi Y, Kawanishi H, Mujais S, et al. Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int 2000; 20 (Suppl 4): S43-S55
20. Davies SJ, Phillips L, Naish PF, et al. Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival. Nephrol Dial Transplant 2002; 17: 1085-1092
21. Lopes Barreto D, Coester AM, NoordzijMet al. Variability of effluent cancer antigen 125 and interleukin-6 determination in peritoneal dialysis patients. Nephrol Dial Transplant 2011; 26: 3739-3744
22. Stelin G, Rippe B. A phenomenological interpretation of the variation in dialysate volume with dwell time in CAPD. Kidney Int 1990; 38: 465-472
23. University of Bristol, Centre for Multilevel Modelling. Referencing the MLwiN software and manuals. http://www.bristol.ac.uk/cmm/software/mlwin/refs.html (24 October 2013, date last accessed
24. Zemel D, Imholz AL, de Waart DR, et al. Appearance of tumor necrosis factor-alpha and soluble TNF-receptors I and II in peritoneal effluent of CAPD. Kidney Int 1994; 46: 1422-1430
25. Margetts PJ, Kolb M, Yu L, et al. Inflammatory cytokines, angiogenesis, and fibrosis in the rat peritoneum. Am J Pathol 2002; 160: 2285-2294
26. Distler JHW, Schett G, Gay S, et al. The controversial role of tumor necrosis factor alpha in fibrotic diseases. Arthritis Rheum 2008; 58: 2228-2235
27. Davies SJ, Bryan J, Phillips L, et al. Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 1996; 11: 498-506
28. Yokoyama K, Yoshida H, Matsuo N, et al. Serum beta2 microglobulin (beta2MG) level is a potential predictor for encapsulating peritoneal sclerosis (EPS) in peritoneal dialysis patients. Clin Nephrol 2008; 69: 121-126